Comparators and indications
• The IV originators and subcutaneous products were considered as comparators.
• The model included the cost of Truxima®, Mabthera® IV and Mabthera® SC for the treatment of their shared indications and the cost of Herzuma®, Herceptin® IV and Herceptin® SC for the corresponding indication profile (Table 1) .
Population
• Population data was obtained at the national level using the Office for National Statistics databases, and for each indication using estimates from a pragmatic literature review.
Market share
• Market share data used in this model were provided by Celltrion Healthcare based on market research. Biosimilar projected market share ranged from 19% to 90% over 5 years. Costs • Payer costs comprised drug acquisition costs and the costs of administering the treatments (informed by NHS staff unit costs) • Drug cost data for biosimilars and all comparators were obtained from the British National Formulary (BNF). • The resource use activities associated with each treatment were based on micro-costing approaches employed by previous publications 1,2 . Sensitivity and scenario analyses • One-way sensitivity analysis was conducted on the base case findings • A scenario analysis adopted the hospital provider perspective and assessed both the financial and resource utilisation impact. • In the UK, biosimilar rituximab and trastuzumab have lower prices than originators but are available only in intravenous (IV) formulations. • Subcutaneous (SC) formulations of the originators rituximab and trastuzumab are both available in the UK. • The market displacement involves direct switches between products with equivalent clinical but different resource use profiles. IV products have been associated with higher administration costs for payers. The trade-off between lower biosimilar drug costs and increased IV administration costs will determine the budget impact of their adoption.
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This study aimed to assess the budget impact of adopting IV biosimilar rituximab (Truxima®) and IV biosimilar trastuzumab (Herzuma®) compared with subcutaneous and IV originators from the perspective of the UK National Health Service (NHS) by evaluating:
• The impact of a switch to the biosimilar on per-patient total spend • The offset between drug and administration costs that occurs with the adoption of the new formulation and the magnitude of cost saving (if applicable) • The additional patients that could be treated with any savings realised. 
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• Increasing biosimilar rituximab and trastuzumab uptake can deliver substantial cost savings for the NHS. • Increased administration costs should not act as a barrier to IV biosimilar uptake as scenario analysis found cost savings to be sensitive to IV biosimilar price but not sensitive to plausible variation in administration costs. • The ability to realise these benefits will depend on price agreed and capacity to deliver larger number of IV infusions.
RESULTS
• Per-patient savings ranged from £2,344 (MPA) to £5,438 (NHL) with biosimilar Truxima® (Figure 2 ) and from £7,837 (MGC) to £12,502 (BC) with biosimilar Herzuma® (Figure 6 ). • At maximum uptake, 76% of SC patients switched to biosimilar Truxima®, resulting in annual savings of £9.9m. If 67% of SC patients switched to biosimilar Herzuma®, the annual saving was £13.5m. • Compared with SC originators, administration costs for IV biosimilars were higher but drug costs were reduced, leading to a lower total cost for IV (Figures 4, 8) . • These cost savings could be used to expand access to 3,594 additional rituximab patients and 2,161 additional trastuzumab patients, with a neutral budget impact (Figures 5, 9 ). • Scenario analysis estimated a positive income impact for a hospital provider, with increased reimbursement revenue outweighing additional IV administration costs. This has implications for expanding access and hospital resource budgets.
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